Recently, to accelerate multi-omics analysis research integrating single-cell and tissue-derived exosomes, Beijing Enze Kangtai Biotechnology Co., Ltd.—dedicated to exosome technology development and clinical translation—has established a strategic partnership with Beijing Xunin Biotechnology Co., Ltd., which possesses dual sequencing capabilities in microporous and droplet technologies.Leveraging their respective technological strengths, the partners will jointly develop single-cell + exosome sequencing analysis products. They will also collaborate on training programs for joint product analysis and deepen strategic cooperation in translational applications. This initiative aims to promote the widespread adoption of single-cell + tissue exosome-tissue microenvironment research solutions, enhance service flexibility and diversity, and ensure solution stability and quality.
Single-cell transcriptome sequencing amplifies and sequences minuscule amounts of total RNA from isolated individual cells. This technology enables analysis of cellular population heterogeneity, definition of cell types, states, and dynamic transitions at the single-cell level, facilitating deeper understanding of transcriptional dynamics and gene regulatory relationships.
Extracellular vesicles (EVs) are nanoscale vesicles secreted by living cells, carrying components such as RNA, proteins, and lipids. They serve as carriers for intercellular communication and are natural tools for studying tissue microenvironments and communication between different cell subpopulations.Tissue-derived EVs, present in the intercellular spaces of tissues, more accurately reflect the EVs secreted by cells within the authentic tissue microenvironment compared to those from cell lines. They also exhibit greater tissue specificity than EVs derived from body fluids such as plasma.Advancements in isolation and characterization techniques for tissue-derived EVs now enable focused studies on EVs within the intercellular spaces of tissue microenvironments. Tissue-derived exosomes have emerged as a focal point in recent exosome research, featured prominently in journals such as Cell and JEV (Journal of Extracellular Vesicles, IF=25.841).
Single-cell transcriptomics offers unparalleled advantages over traditional omics approaches in studying cellular heterogeneity and deciphering tissue microenvironment characteristics due to its high resolution. However, it has limitations in resolving interactions between different cell types within tissues. As a crucial medium for cell-to-cell communication, analyzing the expression patterns of trace amounts of EVs in the tissue microenvironment partially addresses this limitation.
Combining single-cell transcriptomics with tissue exosome analysis allows these two techniques to complement each other's strengths, enabling the dissociation of a single tissue sample to analyze the tissue microenvironment across two dimensions—cell subpopulations and intercellular exosome spaces.uncovering EV communication networks among cellular subpopulations within the microenvironment; tracing the cellular origins of key molecules in tissue exosomes; and mapping EV communication networks between cellular subpopulations in the tissue microenvironment;Constructing comprehensive interaction maps of cellular subpopulations within the microenvironment: revealing ligand-receptor communication based on inter-subpopulation interactions, while integrating tissue-derived exosomes to uncover exosome communication pathways, thereby fully mapping cellular interactions within specific tissue microenvironments;Provide cellular-level and exosomal communication foundations for elucidating disease pathogenesis mechanisms, identifying disease-associated biomarkers and drug targets.
About SeekOne Biotech
SeekOne Biotech is dedicated to universalizing single-cell sequencing technology. As a domestic enterprise possessing both microwell and droplet sequencing capabilities, it has established an end-to-end single-cell sequencing product and service solution spanning from sample preservation and dissociation to bioinformatics analysis.
SeekOne® MM Single-Cell Transcriptome Kit
The flagship product of the microwell chip platform is the SeekOne® MM (Microwell & Magnetic Beads) Single-Cell Transcriptome Kit.requiring no expensive specialized instruments. Using the microwell chip (SeekOne?Chip) and barcoded nucleic acid labeling magnetic beads (BarcodedBeads), it enables single-cell capture and labeling to construct high-throughput single-cell transcriptomic libraries compatible with Illumina sequencers. These libraries undergo sequencing followed by a series of bioinformatics analyses.
The core product of the droplet technology platform is the SeekOne?DD Digital Droplet System and its associated kits. This product has recently completed internal testing and is now recruiting [Experience Ambassadors] nationwide among researchers to launch a free testing campaign for 100 samples.The SeekOne?DD Digital Droplet System will be commercially available shortly, positioning it as China's first domestically developed single-cell droplet technology platform for commercial application, catering to diverse testing needs of experts and scholars nationwide. About Enze Kangtai Beijing Enze Kangtai Biotechnology Co., Ltd. is an innovative high-tech company dedicated to exosome technology development and clinical translation in China.Integrating over a decade of exosome fundamental research with molecular biology and bioinformatics technologies, Enze Kangtai has established an exosome research and translation platform. The company developed the ExoCarta exosome database, co-authored the "Expert Consensus on Exosome Research and Translation," collaborates with over 50 leading hospitals nationwide, has published more than 60 papers, filed 15 invention patents, and maintains a portfolio of 20+ exosome sample types withand over 10,000 samples.
The company's operations span basic research services and innovative drug development using exosomes as carriers. Basic research primarily involves scientific collaborations with clinical experts, supported by a marketing network covering dozens of major Chinese cities. Innovative drug development using exosome carriers focuses on fields including tumor immunology, neurological disorders, and rare diseases. The company is committed to becoming a trusted partner for clinical research by providing systematic exosome research solutions.
Enze Kangtai has developed scRNA-seq+ tissue exosome products—a deep tissue microenvironment research solution. This innovative approach simultaneously performs single-cell transcriptomics and tissue exosome sequencing on the same tissue sample, enabling profound analysis of cellular heterogeneity and intercellular communication within the microenvironment to elevate research output.
With mature experimental techniques and extensive tissue processing expertise, Enze Kangtai has launched tissue exosome research products domestically. The company maintains a comprehensive exosome functional experimentation platform with downstream validation capabilities. Collaborative publications have appeared in high-impact journals including Science, JEV, and NC. Leveraging robust molecular R&D, bioinformatics, and innovation capabilities, Enze Kangtai has pioneered a unique scRNA-seq and tissue EV co-analysis solution, offering customized data mining tailored to scientific questions and datasets.